Youlin Pharma Files for IPO: A Smart CRO Focused on Oncology Clinical Trials

The well-known “722 Incident” in the pharmaceutical industry occurred in 2015, spurring domestic pharmaceutical companies to pivot toward innovative drug development. Subsequently, 2017 was hailed as the inaugural year of innovative drugs in China. It was in this same year that Shanghai Youlin Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Youlin Pharma”) was established in Shanghai. Its founder, Wang Junlin, previously served as general manager of a renowned pharmaceutical company and possesses comprehensive experience spanning the full lifecycle—from development to completion of clinical trials—for nearly ten new drugs, giving him thorough familiarity with the entire new drug R&D process.

“In the early days, I keenly felt that the market lacked truly effective third-party services (CROs), which caused the entire new drug development process to proceed very slowly,” sighed Wang Junlin. “The longer I have been immersed in the industry, the more I have realized that market demands urgently need to be met. If CRO services were highly efficient, their promotional impact on the industry would be significant. Should I embark on entrepreneurship again, I would establish a high-efficiency clinical CRO company to accelerate every stage of drug development within clinical research.”

Guided by this original aspiration and keen insights into the pharmaceutical R&D industry, Wang Junlin chose to focus on clinical research, the most critical phase of new drug development. Youlin Medicine is a clinical research organization dedicated to the oncology field, leveraging intelligent technologies to provide clients with integrated services spanning from strategy to execution. Its service offerings include clinical strategy consulting, study protocol design, clinical monitoring, biostatistics, data management, subject recruitment, bioanalysis, and third-party medical imaging assessment.

Clinical research spans a wide range of therapeutic areas, so why has Youlin Medicine chosen to focus on oncology? Wang Junlin responded, “Sixty percent of innovative drugs in China are new anti-tumor agents. Furthermore, the development of innovative oncology drugs involves high technical barriers. If Youlin Medicine can establish strong expertise in the oncology field, replicating this success in other therapeutic areas will not be overly difficult.”

Many members of Youlin Pharma’s founding team came from the pharmaceutical company where Wang Junlin previously worked. They each bring over a decade of experience in clinical development of new drugs and possess comprehensive expertise in managing the entire value chain of oncology drug R&D. Their deep understanding of sponsors’ needs is a key reason why Youlin Pharma has chosen to focus on the oncology sector.

New drug development is a high-risk, capital-intensive, and long-cycle endeavor, fraught with numerous challenges during clinical research. It is not uncommon for innovative drugs to fail even after reaching Phase III clinical trials, rendering the pharmaceutical companies’ earlier efforts futile. If clinical CROs could assist pharmaceutical companies in making scientific decisions and controlling early-stage R&D costs, it would undoubtedly be a win-win situation.

Amid the current trend toward intelligent operations in clinical research, Youlin Medicine has established specialized teams for big data and intelligent technology development, medical affairs, SMO operations, and data management at research centers. It provides integrated clinical research services, including Clinical Trial Management Systems (CTMS) and Site Management Organization (SMO) services, to clinical research centers and sponsors. This enables pharmaceutical companies to accelerate trial-and-error processes, enhance R&D efficiency, and control R&D costs.

In the field of clinical research, clinical trial efficiency is a critical priority for both sponsors and Contract Research Organizations (CROs), and it remains a major pain point in current clinical research services. Traditional CROs still rely on manual data entry and manual monitoring management; this labor-intensive approach inevitably increases clinical trial costs. To address these pain points in CRO services, Youlin Medicine has proposed solutions from two directions: an Intelligent Clinical Trial Management System and embedded Site Management Organization (SMO) services.

Youlin Medicine has delivered and implemented its proprietary automated data capture system at collaborating clinical research centers. During user operations, the system automatically collects data through instrument interfaces and sample barcodes, and performs automated comparison and management against historical data. This approach minimizes human error and workload, redefines the role of clinical research personnel, and ensures the quality of clinical study deliverables.

“We aim to standardize preclinical service workflows, leveraging systems to manage processes, orchestrate every interaction step, and anchor roles to the workflow. In this way, our final clinical trial deliverables will no longer be constrained by individual personnel; instead, the system itself will ensure high-quality outcomes,” introduced Wang Junlin. “By relying on this system, we can reshape and optimize clinical trial operational procedures, thereby diminishing the significance of human influence.”

Youlin Medicine’s intelligent clinical research collaboration system (eDISC), provided to clinical research centers, enables precise subject recruitment and intelligent guidance for site operations, thereby reducing data error rates, lowering clinical trial costs, improving implementation efficiency, and enhancing the overall quality of research projects.

Unlike traditional CRO services, this innovative service and the clinical research process under its system management can shorten clinical trial duration by approximately one-third, equivalent to saving pharmaceutical companies 30% in costs.

Effective clinical research services rely on professional and scientific medical support throughout the entire process. From the initial project initiation, Youlin Medicine develops clinical research strategies for target products based on clinical needs and market conditions, ensuring that the entire clinical study is both forward-looking and adaptable, enabling dynamic decision-making. This results in a trial protocol that is recognized and adhered to by all stakeholders, taking into account comprehensive factors such as budget, timeline, success rate, feasibility, safety, and risk. During the conduct of clinical trials, we also provide rapid responses to all medical issues, offering judgments and corresponding solutions to minimize risks to subjects and ensure trial quality.

It is reported that Youlin Medicine has maintained long-term, strong collaborative relationships with key principal investigators (PIs) in oncology across China, engaging over 200 collaborating researchers and image review experts. All projects undertaken involve innovative oncology drugs for registrational clinical trials, with the leading PIs serving as chairpersons of the Chinese Society of Clinical Oncology (CSCO). These resources, advantages, and extensive project experience have further solidified Youlin Medicine’s industry position in the field of oncology.

Regarding the future, Wang Junlin also stated that the company will continue to focus on the oncology sector and persist in systematically optimizing its CRO model. Over the next three years, it plans to further expand its team and attract more industry professionals to join.